MedPath

INSTITUTO GRIFOLS SA

🇪🇸Spain
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

Phase 3
Withdrawn
Conditions
Congenital Afibrinogenemia
Hypofibrinogenemia
Interventions
Biological: FIB Grifols
First Posted Date
2020-11-19
Last Posted Date
2023-10-23
Lead Sponsor
Instituto Grifols, S.A.
Registration Number
NCT04636268

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Convalescent anti-SARS-CoV-2 MBT Plasma
Drug: Standard Medical Treatment
First Posted Date
2020-09-14
Last Posted Date
2021-03-03
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
200
Registration Number
NCT04547127
Locations
🇪🇸

Hospital General Universitario de Alicante, Alicante, Spain

🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

🇪🇸

Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain

and more 9 locations

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Prolastin
Drug: Standard Medical Treatment
First Posted Date
2020-07-31
Last Posted Date
2021-07-08
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
100
Registration Number
NCT04495101
Locations
🇪🇸

Hospital Universitario de Burgos, Burgos, Castilla León, Spain

🇪🇸

Hospital Universitari Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Clínic de Barcelona, Barcelona, Spain

and more 6 locations

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Intravenous Immune Globulin
Drug: Standard Medical Treatment
First Posted Date
2020-06-16
Last Posted Date
2021-03-10
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
100
Registration Number
NCT04432324
Locations
🇪🇸

Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain

🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Del Mar, Barcelona, Spain

and more 7 locations

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Phase 3
Completed
Conditions
Excessive Bleeding During Surgery
Interventions
Biological: Fibrin Sealant Grifols
Biological: EVICEL
First Posted Date
2018-03-12
Last Posted Date
2023-04-14
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
186
Registration Number
NCT03461406
Locations
🇺🇸

Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

University of Michigan, Michigan Center, Michigan, United States

🇺🇸

The Urological Institute of Northeastern New York, Albany, New York, United States

and more 37 locations

Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Biological: Albumin
First Posted Date
2015-06-24
Last Posted Date
2020-06-16
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
13
Registration Number
NCT02479802
Locations
🇪🇸

Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome

Phase 2
Terminated
Conditions
Post-polio Syndrome
Interventions
Biological: Flebogamma 5% DIF
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2023-11-27
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
191
Registration Number
NCT02176863
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

🇺🇸

SUNY Upstate Medical University, Syracuse, New York, United States

🇺🇸

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 18 locations

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

Phase 2
Completed
Conditions
Hemostasis
Interventions
Biological: Human thrombin
Biological: Bovine thrombin
First Posted Date
2013-12-18
Last Posted Date
2017-06-14
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
181
Registration Number
NCT02014402
Locations
🇺🇸

805, Tucson, Arizona, United States

🇺🇸

602, Los Angeles, California, United States

🇺🇸

700, 801, Pasadena, California, United States

and more 17 locations

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Phase 3
Completed
Conditions
Parenchymous Tissue Surgical Bleeding
Interventions
Device: Surgicel®
Biological: Fibrin Sealant Grifols
First Posted Date
2012-12-21
Last Posted Date
2017-02-08
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
325
Registration Number
NCT01754480
Locations
🇺🇸

224, Loma Linda, California, United States

🇺🇸

214, Los Angeles, California, United States

🇺🇸

213, New Haven, Connecticut, United States

and more 30 locations

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

Phase 3
Completed
Conditions
Vascular Surgical Bleeding
Interventions
Biological: Fibrin Sealant Grifols
Procedure: Manual Compression
First Posted Date
2012-08-10
Last Posted Date
2017-04-06
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
225
Registration Number
NCT01662856
Locations
🇺🇸

407, Florence, Alabama, United States

🇺🇸

125, Palo Alto, California, United States

🇺🇸

119, San Diego, California, United States

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath